| NEWS | Bausch + Lomb IPO comes into focus: What you need to know | | Bausch + Lomb, which specializes in selling contact lenses, eye drops, and more, is expected to begin trading on the New York Stock Exchange and the Toronto Stock Exchange on Friday under the “BLCO” ticker. | | | The IPO comes almost two years after Bausch Health initially announced it would spin off Bausch + Lomb in an effort to streamline its operations and reduce debt. | | | Shares were priced at $18, lower than their expected range of $21 - $24, signaling that investor appetite might not be as high as hoped. | | | The IPO market has been in a rout this year, due in part to investor wariness and Russia’s invasion of Ukraine, among other factors. Bausch + Lomb’s listing is one of the most high-profile IPOs so far. | | Check out the latest news stories here. | | | | | | | |